Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 28, 2023 08:00 ET | Source: Immutep Limited

First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Media Release SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
June 27, 2023 08:00 ET | Source: Immutep Limited

Immutep Completes A$80 Million Capital Raise

Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
June 27, 2023 08:00 ET | Source: Immutep Limited

Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor

Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer...
June 20, 2023 08:00 ET | Source: Immutep Limited

Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3

Media Release SYDNEY, AUSTRALIA, June 20, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer...
June 07, 2023 08:00 ET | Source: Immutep Limited

Immutep to Participate at the Jefferies Healthcare Conference

SYDNEY, AUSTRALIA, June 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3...
June 05, 2023 08:00 ET | Source: Immutep Limited

Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting

Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response not reached despite median follow up of 39 months in...
June 02, 2023 08:00 ET | Source: Immutep Limited

Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer

Sydney, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) (Immutep or the Company), is pleased to announce the successful completion of an...
May 29, 2023 08:00 ET | Source: Immutep Limited

Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study

Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP761Forms a key step prior to...
May 26, 2023 08:00 ET | Source: Immutep Limited

Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting

Media Release New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinomaDeep, durable...
May 25, 2023 08:00 ET | Source: Immutep Limited

Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Media Release SYDNEY, AUSTRALIA, May 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...